Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (735)	2/18/1998 8:11:00 AM
From: BD	Read Replies (1) \| Respond to of 887

Two other views on this situation; first is the issue of the statistics problem of the 7 patients Depo said were not evaluable. If this can be upheld then the 33% vs 17% response rate is so significant the chemical arachnoiditis will become a less important issue. The second point I'd like to bring out is that I think if you mix a little morphine with the cytabine it might be tollorated better, (depo joke).